A polymeric prodrug of cisplatin based on pullulan for the targeted therapy against hepatocellular carcinoma

International Journal of Pharmaceutics

Volumn 483, Issue 1-2, 2015, Pages 89-100

  Wang, Yan ^a   Liu, Yuanyuan ^a   Liu, Yang ^a   Zhou, Wen ^a   Wang, Hemei ^a   Wan, Guoyun ^a   Sun, Duxin ^b   Zhang, Ning ^a   Wang, Yinsong ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cisplatin; Hepatocellular carcinoma; Prodrug; Pullulan; Targeted therapy

Indexed keywords

CISPLATIN; GENOMIC DNA; PRODRUG; PULLULAN; PULLULAN MONOSUCCINATE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; POLYMER;

A549 CELL LINE; ACUTE TOXICITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL NUCLEUS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA REPLICATION; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG SYNTHESIS; HEPG2 CELL LINE; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; SUSTAINED DRUG RELEASE; ANIMAL; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; FEMALE; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR STRUCTURE; POLYMERS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923027888     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.02.027     Document Type: Article

References (39)

1. Almhanna, K., Kalmadi, S., Pelley, R., Kim, R., 2007. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach? Oncology (Williston Park) 21, 1116-1122.
2. Banerjee, S.S., Aher, N., Patil, R., Khandare, J., 2012. Poly(ethylene glycol)-prodrug conjugates: concept, design, and applications. J. Drug Deliv. 2012, 103973.
3. Bishwambhar, M., Suneetha, V., Ramalingam, C., 2011. An overview of characterization and optimization of pullulan producing microorganism. SAJEB 1, 147-151.
4. Chen, H., Landen, C.N., Li, Y., Alvarez, R.D., Tollefsbol, T.O., 2013. Enhancement of cisplatin-mediated apoptosis in ovarian cancer cells through potentiating G2/M arrest and p21 upregulation by combinatorial epigallocatechin gallate and sulforaphane. J. Oncol. 2013, 872957.
5. D'Alessandro, N., Poma, P., Montalto, G., 2007. Multifactorial nature of hepatocellular carcinoma drug resistance: could plant polyphenols be helpful? World J. Gastroenterol. 13, 2037-2043.
6. Florea, A.M., Büsselberg, D., 2011. Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers 3, 1351-1371.
7. Flores, A., Marrero, J.A., 2014. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin. Med. Insights Oncol. 8, 71-76.
8. Goodarzi, N., Varshochian, R., Kamalinia, G., Atyabi, F., Dinarvand, R., 2013. A review of polysaccharide cytotoxic drug conjugates for cancer therapy. Carbohydr. Polym. 92, 1280-1293.
9. Greco, F., Vicent, M.J., 2009. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 61, 1203-1213.
10. Guhagarkar, S.A., Majee, S.B., Samad, A., Devarajan, P.V., 2011. Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line. Cancer Nano 2, 49-55.
11. Hirayama, F., Uekama, K., 1999. Cyclodextrin-based controlled drug release system. Adv. Drug Deliv. Rev. 36, 125-141.
12. Kaneo, Y., Tanaka, T., Nakano, T., Yamaguchi, Y., 2001. Evidence for receptor-mediated hepatic uptake of pullulan in rats. J. Control. Release 70, 365-373.
13. Kelland, L., 2007. The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7, 573-584.
14. Kratz, F., 2007. DOXO-EMCH (INNO-206): the first albumin-binding prodrug of doxorubicin to enter clinical trials. Expert Opin. Investig. Drugs 16, 855-866.
15. Kratz, F., Müller, I.A., Ryppa, C., Warnecke, A., 2008. Prodrug strategies in anticancer chemotherapy. ChemMedChem 3, 20-53.
16. Lee, W.Y., Cheung, C.C., Liu, K.W., Fung, K.P., Wong, J., Lai, P.B., Yeung, J.H., 2010. Cytotoxic effects of tanshinones from Salvia miltiorrhiza on doxorubicin-resistant human liver cancer cells. J. Nat. Prod. 73, 854-859.
17. Li, C., Wallace, S., 2008. Polymer-drug conjugates: recent development in clinical oncology. Adv. Drug Deliv. Rev. 60, 886-898.
18. Lu, Y.H., Gao, X.Q., Wu, M., Zhang-Negrerie, D., Gao, Q., 2011. Strategies on the development of small molecule anticancer drugs for targeted therapy. Mini Rev. Med. Chem. 11, 611-624.
19. Palipoch, S., Punsawad, C., 2013. Biochemical and histological study of rat liver and kidney injury induced by cisplatin. J. Toxicol. Pathol. 26, 293-299.
20. Pasut, G., Veronese, F.M., 2009. PEG conjugates in clinical development or use as anticancer agents: an overview. Adv. Drug Deliv. Rev. 61, 1177-1188.
21. Qin, L.F., Ng, I.O., 2002. Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. Cancer Lett. 175, 27-38.
22. Ren, Y., Wang, R., Liu, Y., Guo, H., Zhou, X., Yuan, X., Liu, C., Tian, J., Yin, H., Wang, Y., Zhang, N., 2014. A hematoporphyrin-based delivery system for drug resistance reversal and tumor ablation. Biomaterials 35, 2462-2470.
23. Rosenberg, B., VanCamp, L., Trosko, J.E., Mansour, V.H., 1969. Platinum compounds: a new class of potent antitumour agents. Nature 222, 385-386.
24. Roy, A., Bhattacharyya, M., Ernsting, M.J., May, J.P., Li, S.D., 2014. Recent progress in the development of polysaccharide conjugates of docetaxel and paclitaxel. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 6, 349-368.
25. Sanchis, J., Canal, F., Lucas, R., Vicent, M.J., 2010. Polymer-drug conjugates for novel molecular targets. Nanomedicine (Lond) 5, 915-935.
26. Sarma, M.P., Asim, M., Medhi, S., Bharathi, T., Diwan, R., Kar, P., 2012. Viral genotypes and associated risk factors of hepatocellular carcinoma in India. Cancer Biol. Med. 9, 172-181.
27. Schütte, K., Bornschein, J., Malfertheiner, P., 2009. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig. Dis. 27, 80-92.
28. Sohn, J.S., Jin, J.I., Hesscd, M., Jo, B.W., 2010. Polymer prodrug approaches applied to paclitaxel. Polym. Chem. 1, 778-792.
29. Tang, H.B., Li, L., Chen, H., Zhou, Z.M., Chen, H.L., Li, X.M., Liu, L.R., Wang, Y.S., Zhang, Q.Q., 2010. Stability and in vivo evaluation of pullulan acetate as a drug nanocarrier. Drug Deliv. 17, 552-558.
30. Varshosaz, J., 2012. Dextran conjugates in drug delivery. Expert Opin. Drug Deliv. 9, 509-523.
31. Venook, A.P., Papandreou, C., Furuse, J., de Guevara, L.L., 2010. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 15, 5-13.
32. Veronese, F.M., Schiavon, O., Pasut, G., Mendichi, R., Andersson, L., Tsirk, A., Ford, J., Wu, G., Kneller, S., Davies, J., Duncan, R., 2005. PEG-doxorubicin conjugates: influence of polymer structure on drug release in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug. Chem. 16, 775-784.
33. Wang, Y., Chen, H., Liu, Y., Wu, J., Zhou, P., Wang, Y., Li, R., Yang, X., Zhang, N., 2013a. pH-sensitive pullulan-based nanoparticle carrier of methotrexate and combretastatin A4 for the combination therapy against hepatocellular carcinoma. Biomaterials 34, 7181-7190.
34. Wang, Z., Zhang, G., Wu, J., Jia, M., 2013b. Adjuvant therapy for hepatocellular carcinoma: current situation and prospect. Drug Discov. Ther. 7, 137-143.
35. Ye, H., Jin, L., Hu, R., Yi, Z., Li, J., Wu, Y., Xi, X., Wu, Z., 2006. Poly(γ,L-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials 27, 5958-5965.
36. Zamble, D.B., Lippard, S.J., 1995. Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem. Sci. 20, 435-439.
37. Zhai, B., Hu, F., Jiang, X., Xu, J., Zhao, D., Liu, B., Pan, S., Dong, X., Tan, G., Wei, Z., Qiao, H., Jiang, H., Sun, X., 2014. Inhibition of akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol. Cancer Ther. 13, 1589-1598.
38. Zhang, W.H., Poh, A., Fanous, A.A., Eastman, A., 2008. DNA damage-induced S phase arrest in human breast cancer depends on Chk1, but G2 arrest can occur independently of Chk1, Chk2 or MAPKAPK2. Cell Cycle 7, 1668-1677.
39. Zhang, X.D., Wang, Y., Ye, L.H., 2014. Hepatitis B virus X protein accelerates the development of hepatoma. Cancer Biol. Med. 11, 182-190.